Challenges of COVID-19 and Tuberculosis - Urgent Need to Tackle the Dual Burden

The COVID-19 disease has currently overwhelmed all other health issues throughout the world. There can be many repercussions on existing public health issues, especially tuberculosis (TB), which is endemic in many low and middle-income countries (LMICs). In most of the LMICs, the health services are poorly equipped, the resources being diverted to control the pandemic of COVID-19, which can lead to grave consequences for LMICs. COVID-19 and TB are known to affect the respiratory system, so their symptoms are very similar, and at times can be perplexing for diagnosis. Moreover, lack of proper treatment and vaccine for COVID19 can further increase the mounting pressure. Synthetic drugs, such as hydroxychloroquine, are currently being used, but the side effects are a cause of concern. Hence, the efficacy of repositioned drugs is still under evaluation. The situation is further worsened by the possible development of drug-resistant mutants. What we need in current times is potential novel anti-viral drugs that are highly productive and economic in control and management of viral infections in LMICs. The only option which we can look upon is the natural products which are also known as bioactive compounds and their phytochemicals like flavonoids, alkaloids and peptides that have anti-viral secondary metabolites which have shown promising results on COVID-19. This review systematically emphasizes the urgency for treatment options, which can be both safe and effective, especially for TB patients from LMICs.